108-29-2
CAS 108-29-2
108-29-2 (CAS 108-29-2) is a pharmaceutical compound with 1 bioactivity target and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Ki | 35203.333333333336 nM | 3 | - |
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| carbonic anhydrase 9 CA9 |
Inhibition | 6.039999961853027 pKi | 22137345 |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is 108-29-2 used for in pharmaceutical contexts?
108-29-2 (CAS 108-29-2) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for 108-29-2?
No adverse-event association or SIDER side-effect rows are rendered for 108-29-2 in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is 108-29-2 also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for gamma-Valerolactone with EU status "permitted".
What clinical phase is 108-29-2 in?
No phase 1-4 clinical development badge is rendered for 108-29-2 because the matched compound identifier rows do not contain a max-phase value.